Publication
Article
BP Elements
Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service
Author(s):
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.
Eurofins Genomics Blue Heron, a biotechnology company specializing in advanced gene synthesis, announced the launch of its in-vitro transcription (IVT) messenger RNA (mRNA) synthesis service on June 29, 2023. According to a company press release, the new synthesis service is designed to offer a comprehensive solution for researchers seeking high-quality, customizable mRNA synthesis with fast turnaround times.
According to the release, the new synthesis service is equipped to handle various applications and includes customizable mRNA synthesis capabilities to meet specific research needs. It is designed for use in molecular biology, drug discovery, vaccine development, and gene therapy, among other fields.
Source: Eurofins Genomics
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
